AgomAb Therapeutics
Company Snapshot
AgomAb Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for patients with unmet medical needs. The company's lead product candidates include ontunisertib and AGMB-447, which are aimed at treating various conditions. Their business model revolves around advancing clinical development and leveraging existing cash and proceeds from the IPO to fund future growth.
Key Financials
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | Not provided | Not provided |
| Adjusted Net Loss | -$46.3M | -$11.4M |
Balance Sheet
S-1 Highlights
Market & Competition
The company operates in the biotechnology sector, which is characterized by high competition and rapid innovation. AgomAb Therapeutics competes with other biopharmaceutical companies, although specific competitor names were not mentioned in the filing.
Use of Proceeds
The net proceeds from the IPO are estimated to be approximately $182 million, which the company intends to use to advance clinical development of its product candidates, fund preclinical candidates, and cover general corporate expenses.
Key Risk Factors
- ●The company faces significant risks related to the high failure rate of drugs in clinical trials, which could adversely affect their business prospects.
- ●There is currently no established endpoint for therapies targeting FSCD, which may delay the development of their product candidates or increase costs.
Deal Structure
Reported Broker Availability
E*TRADEReported by users or publicly disclosed. Information is for reference only.